-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vorinostat in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorinostat in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorinostat in Marginal Zone B-cell Lymphoma Drug Details: Vorinostat...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Refractory Acute Myeloid Leukemia Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DA-5216 in Idiopathic (Essential) Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DA-5216 in Idiopathic (Essential) Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DA-5216 in Idiopathic (Essential) HypertensionDrug Details:DA-5216 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Idiopathic Membranous Nephropathy in Membranous Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Idiopathic Membranous Nephropathy in Membranous Glomerulonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Idiopathic Membranous Nephropathy in Membranous GlomerulonephritisDrug Details:The therapeutic candidate is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGN-ALPV in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SGN-ALPV in Gastroesophageal (GE) Junction Carcinomas Drug Details: SGN-ALPV is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Simurosertib in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Simurosertib in Ovarian Cancer Drug Details: TAK-931 is under development for the treatment of advanced...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Serabelisib in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Serabelisib in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Serabelisib in Colorectal Cancer Drug Details:Serabelisib (TAK-117, INK1117) is under development for solid...
-
Sector Analysis
Heart Failure Epidemiology Analysis and Forecast to 2032
Heart Failure Epidemiology Analysis Report Overview In the 7MM, there were 3,094,817 diagnosed incident cases of heart failure in 2022 and will grow at an AGR of more than 1% during 2022-2032. Heart failure (HF) is a condition characterized by the reduced ability of the heart to pump and/or fill with blood. It is a lifelong condition in which the heart muscle cannot pump enough blood to meet the body’s needs for blood and oxygen. HF is diagnosed through blood...
-
Product Insights
Cali ARB – Iowa Avenue Research and Testing Facility – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our Cali ARB - Iowa Avenue Research and Testing Facility - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
USACE – Grissom ARB Repair Airport Runway and Taxiway – Indiana
Equip yourself with the essential tools needed to make informed and profitable decisions with our USACE - Grissom ARB Repair Airport Runway and Taxiway - Indiana report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...